Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 5/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CDC25A | P30304 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508801 | 0.79 | CDC25B (0.43) | CDC25BIDO1MAOAMAOBAKT1 | |
| SCHEMBL30229349 | 0.75 | IDO1 (0.46) | CDC25BIDO1MAOAMAOBAKT1 | |
| SCHEMBL8893539 | 0.74 | TOP1 (0.53) | IDO1TOP1ALDH1A1LMNAMAPT | |
| SCHEMBL6917185 | 0.71 | IDO1 (0.52) | CDC25BIDO1MAOAMAOBAKT1 | |
| SCHEMBL18838823 | 0.66 | CDC25A (0.41) | CDC25BIDO1MAOAMAOBSNCA | |
| SCHEMBL17441737 | 0.65 | HKDC1 (0.31) | CDC25BALDH1A1LMNAMAPTCDC25A | |
| SCHEMBL9861418 | 0.64 | PDK2 (0.48) | CDC25BIDO1MAOAMAOBAKT1 | |
| SCHEMBL11490745 | 0.64 | MAPT (0.46) | CDC25BIDO1MAOAALDH1A1LMNA | |
| SCHEMBL17441447 | 0.63 | — | — | |
| SCHEMBL11493691 | 0.63 | MAPT (0.45) | CDC25BIDO1MAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404659-B1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2010-02-10 | — | — | EP | disclosed |
| EP-1572197-B1 | 4- 1- (SULFONYL) -1H-INDOL-2-YL)-4- (HYDROXY) -CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1572197-B1 | 4- 1- (SULFONYL) -1H-INDOL-2-YL)-4- (HYDROXY) -CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| US-7144893-B2 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1572197-A1 | 4- 1- (SULFONYL) -1H-INDOL-2-YL)-4- (HYDROXY) -CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-11-04 | — | — | US | disclosed |
| WO-2004056361-A1 | 4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1404659-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | CDC25B 660/4885IDO1 106/4885MAOA 281/4885 |
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | TXNRD3, TXNRD1, TXN | CDC25B 423/4885IDO1 511/4885MAOA 566/4885 |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | CDC25B 424/4885IDO1 165/4885MAOA 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.